Nan Lin

TL;DR: The efficacy and toxicity data from the available trials of endocrine therapy in the postmenopausal setting are reviewed, controversies in choosing the optimal endocrine approach are outlined, and the need to understand host and tumor heterogeneity is highlighted.

TL;DR: It is demonstrated that co-treatment with irreversible pan-HER inhibitors enhances receptor ubiquitination and consequent ADC internalization and efficacy, and that ADC switching to T-DXd, which harbors a different cytotoxic payload, achieves durable responses in a patient with lung cancer and corresponding xenograft model developing resistance toT-DM1.

TL;DR: Data indicate that normal human endothelial cells produce SCF and show high-affinity c-kit receptors that have the capacity to dimerize and may serve to regulate the bioactivity of SCF within the bone marrow microenvironment.

TL;DR: Clinical trials of brain metastases in relation to measures of clinical benefit are reviewed to provide a framework for the design and conduct of future trials.

TL;DR: Among patients with mTNBC treated with anti-PD-1/L1 therapies, high TMB and PTEN alterations were associated with longer and shorter survival, respectively, which warrant validation in larger datasets.